HATICE
Healthy Aging Through Internet Counselling in the Elderly
| Coordinatore | Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Sito del progetto | http://www.hatice.eu/ |
| Totale costo | 7˙423˙520 € |
| EC contributo | 5˙824˙039 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-01-01 - 2017-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | coordinator | 1˙994˙679.00 |
| 2 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 1˙227˙480.00 |
| 3 |
Nome Ente NON disponibile
Organization address
address: YLIOPISTONRANTA 1 E contact info |
FI (Kuopio) | participant | 1˙011˙480.00 |
| 4 |
VITALHEALTH SOFTWARE BV
Organization address
address: ZONNEOORDLAAN 17 contact info |
NL (EDE GLD) | participant | 755˙000.00 |
| 5 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 416˙860.00 |
| 6 |
NOVAPTEN SARL
Organization address
address: RUE CHARLES V 14 contact info |
FR (PARIS) | participant | 323˙920.00 |
| 7 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 94˙620.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Diabetes mellitus, hypertension, obesity, hypercholesterolemia, smoking and physical inactivity are common in elderly persons and are all associated with an increased risk of myocardial infarction, stroke and dementia. Efficacious treatments of these cardiovascular diseases are available, but in elderly patients with multiple cardiovascular diseases and risk factors however, treatment is currently insufficient. Optimisation of management of these diseases in order to decrease the burden of cardiovascular disease and its long-term complications is urgently needed. In this project we will develop and evaluate an innovative intervention strategy to improve pharmacological and non-pharmacological treatment for cardiovascular disease in elderly patients. First, data from three large ongoing clinical trials on multi-component vascular interventions in the elderly will be used to explore efficacy and feasibility of various treatment regimens. Second, an innovative and interactive internet platform for self-management of vascular diseases in the elderly will be developed. Interactive support by practice nurses and patient’s own physician and monitoring of adverse events will be integrated. Third, the efficacy of access to this new internet platform will be evaluated in a randomised controlled trial in 5400 elderly with multiple cardiovascular diseases. Patients randomised to the control condition will receive regular care. Primary outcome is optimisation of management of cardiovascular diseases. Secondary outcomes are new cardiovascular events, handicap, cognition and survival. This flexible internet-based intervention strategy can be easily translated and adapted for use in different health-care systems in the EU. It will allow for tailor-made interventions specifically suited to the needs of older people and meticulous monitoring of side effects. The expected decrease in new cardiovascular events and dementia will result in lowering of healthcare costs substantially.'
Introduzione (Teaser)
Treatment methods do not sufficiently meet the needs of older people who suffer from several health problems at the same time. An EU initiative is creating an innovative intervention strategy to optimally manage multiple cardiovascular risk factors and diseases.